SynAct Pharma AB
STO:SYNACT
Intrinsic Value
The intrinsic value of one SYNACT stock under the Base Case scenario is 42.1 SEK. Compared to the current market price of 19.04 SEK, SynAct Pharma AB is Undervalued by 55%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
SynAct Pharma AB
Loading...
Fundamental Analysis

Revenue & Expenses Breakdown
SynAct Pharma AB
Balance Sheet Decomposition
SynAct Pharma AB
Current Assets | 72.8m |
Cash & Short-Term Investments | 51.2m |
Receivables | 15.4m |
Other Current Assets | 6.2m |
Non-Current Assets | 146.4m |
Long-Term Investments | 136k |
PP&E | 1.7m |
Intangibles | 144.5m |
Free Cash Flow Analysis
SynAct Pharma AB
SEK | |
Free Cash Flow | SEK |
Earnings Waterfall
SynAct Pharma AB
Revenue
|
0
SEK
|
Operating Expenses
|
-92.4m
SEK
|
Operating Income
|
-92.4m
SEK
|
Other Expenses
|
10.2m
SEK
|
Net Income
|
-82.2m
SEK
|
SYNACT Profitability Score
Profitability Due Diligence
SynAct Pharma AB's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
SynAct Pharma AB's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
SYNACT Solvency Score
Solvency Due Diligence
SynAct Pharma AB's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
SynAct Pharma AB's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SYNACT Price Targets Summary
SynAct Pharma AB
According to Wall Street analysts, the average 1-year price target for SYNACT is 25.5 SEK with a low forecast of 25.25 SEK and a high forecast of 26.25 SEK.
Dividends
Current shareholder yield for SYNACT is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one SYNACT stock under the Base Case scenario is 42.1 SEK.
Compared to the current market price of 19.04 SEK, SynAct Pharma AB is Undervalued by 55%.